These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 7906384

  • 1. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. The Terry Beirn Community Programs for Clinical Research on AIDS.
    Abrams DI, Goldman AI, Launer C, Korvick JA, Neaton JD, Crane LR, Grodesky M, Wakefield S, Muth K, Kornegay S.
    N Engl J Med; 1994 Mar 10; 330(10):657-62. PubMed ID: 7906384
    [Abstract] [Full Text] [Related]

  • 2. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, Markowitz N, Reves R, Loveless MO, Crane L, Thompson M, Abrams D.
    N Engl J Med; 1996 Oct 10; 335(15):1099-106. PubMed ID: 8813040
    [Abstract] [Full Text] [Related]

  • 3. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team.
    Hammer SM, Katzenstein DA, Hughes MD, Gundacker H, Schooley RT, Haubrich RH, Henry WK, Lederman MM, Phair JP, Niu M, Hirsch MS, Merigan TC.
    N Engl J Med; 1996 Oct 10; 335(15):1081-90. PubMed ID: 8813038
    [Abstract] [Full Text] [Related]

  • 4. Treatment options in zidovudine intolerance or failure.
    Abrams DI.
    AIDS; 1994 Sep 10; 8 Suppl 3():S3-7. PubMed ID: 7840914
    [Abstract] [Full Text] [Related]

  • 5. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group.
    Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, Brown M, Volberding PA, Crumpacker CS, Beall G.
    N Engl J Med; 1992 Aug 27; 327(9):581-7. PubMed ID: 1353607
    [Abstract] [Full Text] [Related]

  • 6. A comparison of zidovudine, didanosine, zalcitabine and no antiretroviral therapy in patients with advanced HIV disease.
    Torres RA, Barr MR, McIntyre KI, Thornton JR, Shay WM, Feldman RD, George NJ, Britton DJ.
    Int J STD AIDS; 1995 Aug 27; 6(1):19-26. PubMed ID: 7727578
    [Abstract] [Full Text] [Related]

  • 7. Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Wellcome Resistance Study Collaborative Group.
    Schooley RT, Ramirez-Ronda C, Lange JM, Cooper DA, Lavelle J, Lefkowitz L, Moore M, Larder BA, St Clair M, Mulder JW, McKinnis R, Pennington KN, Harrigan PR, Kinghorn I, Steel H, Rooney JF.
    J Infect Dis; 1996 Jun 27; 173(6):1354-66. PubMed ID: 8648207
    [Abstract] [Full Text] [Related]

  • 8. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. The NIAID AIDS Clinical Trials Group.
    Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC, Powderly WG.
    Ann Intern Med; 1995 Jan 01; 122(1):24-32. PubMed ID: 7985892
    [Abstract] [Full Text] [Related]

  • 9. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy.
    Fischl MA, Olson RM, Follansbee SE, Lalezari JP, Henry DH, Frame PT, Remick SC, Salgo MP, Lin AH, Nauss-Karol C, Lieberman J, Soo W.
    Ann Intern Med; 1993 May 15; 118(10):762-9. PubMed ID: 8097082
    [Abstract] [Full Text] [Related]

  • 10. Combination therapy with ZDV + DDI versus ZDV + DDC in patients with progression of HIV-infection under treatment with ZDV.
    Mauss S, Adams O, Willers R, Jablonowski H.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Apr 15; 11(5):469-77. PubMed ID: 8605592
    [Abstract] [Full Text] [Related]

  • 11. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team.
    Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, Rasheed S, Elbeik T, Reichman R, Japour A, Merigan TC, Hirsch MS.
    N Engl J Med; 1996 Oct 10; 335(15):1091-8. PubMed ID: 8813039
    [Abstract] [Full Text] [Related]

  • 12. A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team.
    Henry K, Erice A, Tierney C, Balfour HH, Fischl MA, Kmack A, Liou SH, Kenton A, Hirsch MS, Phair J, Martinez A, Kahn JO.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec 01; 19(4):339-49. PubMed ID: 9833742
    [Abstract] [Full Text] [Related]

  • 13. Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group.
    Lancet; 1999 Jun 12; 353(9169):2014-25. PubMed ID: 10376616
    [Abstract] [Full Text] [Related]

  • 14. Response of CD4 lymphocytes and clinical consequences of treatment using ddI or ddC in patients with advanced HIV infection.
    Goldman AI, Carlin BP, Crane LR, Launer C, Korvick JA, Deyton L, Abrams DI.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Feb 01; 11(2):161-9. PubMed ID: 8556398
    [Abstract] [Full Text] [Related]

  • 15. Risk factors for dideoxynucleoside-induced toxic neuropathy in patients with the human immunodeficiency virus infection.
    Fichtenbaum CJ, Clifford DB, Powderly WG.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Oct 01; 10(2):169-74. PubMed ID: 7552481
    [Abstract] [Full Text] [Related]

  • 16. Switching from zidovudine to didanosine in patients with symptomatic HIV infection and disease progression. ddI Iberian Study Group.
    Gatell JM, González-Lahoz J, Clotet B, Antunes F, Kasparova L, Gil-Aguado A, Saballs P, Santamaria JM, Podzamczer D, Miro JM, Jou A, Verdejo J, Doroana M, Thomis J.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Jul 01; 12(3):249-58. PubMed ID: 8673528
    [Abstract] [Full Text] [Related]

  • 17. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators.
    D'Aquila RT, Hughes MD, Johnson VA, Fischl MA, Sommadossi JP, Liou SH, Timpone J, Myers M, Basgoz N, Niu M, Hirsch MS.
    Ann Intern Med; 1996 Jun 15; 124(12):1019-30. PubMed ID: 8633815
    [Abstract] [Full Text] [Related]

  • 18. Didanosine compared with continuation of zidovudine in HIV-infected patients with signs of clinical deterioration while receiving zidovudine. A randomized, double-blind clinical trial. The Bristol-Myers Squibb AI454-010 Study Group.
    Spruance SL, Pavia AT, Peterson D, Berry A, Pollard R, Patterson TF, Frank I, Remick SC, Thompson M, MacArthur RD, Morey GE, Ramirez-Ronda CH, Bernstein BM, Sweet DE, Crane L, Peterson EA, Pachucki CT, Green SL, Brand J, Rios A, Dunkle LM, Cross A, Brown MJ, Ingraham P, Gugliotti R, Schindzielorz AH, Smaldone L.
    Ann Intern Med; 1994 Mar 01; 120(5):360-8. PubMed ID: 7905722
    [Abstract] [Full Text] [Related]

  • 19. Didanosine compared with continued zidovudine therapy for HIV-infected patients with 200 to 500 CD4 cells/mm3. A double-blind, randomized, controlled trial. Canadian HIV Trials Network Protocol 002 Study Group.
    Montaner JS, Schechter MT, Rachlis A, Gill J, Beaulieu R, Tsoukas C, Raboud J, Cameron B, Salomon H, Dunkle L, Smaldone L, Wainberg MA.
    Ann Intern Med; 1995 Oct 15; 123(8):561-71. PubMed ID: 7677296
    [Abstract] [Full Text] [Related]

  • 20. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults.
    Darbyshire J, Foulkes M, Peto R, Duncan W, Babiker A, Collins R, Hughes M, Peto T, Walker A.
    Cochrane Database Syst Rev; 2000 Oct 15; 2000(2):CD002038. PubMed ID: 10796851
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.